Medical net May 16, the 2016 medical circulation, retail top 100 list, the top 20 just announced! 

 

Yesterday (May 15), sponsored by the association of Chinese pharmaceutical business "2017 Chinese medicine circulation industry supply side innovation BBS" was held in Shanghai, the ministry of commerce and national development planning commission, the food administration of drug safety, people club department leaders to attend the BBS and speech. 

 

On BBS, we released the list of the top 100 drug wholesalers and retail stores in 2016. 

 

▍ pharmaceutical wholesale enterprises growth is slowing 

 

2016 pharmaceutical wholesale enterprises advocate business wu income before three grew by 11.0% year on year, the top 10 year-on-year growth of 12.5%, up 14.5% from a year earlier, the top 50 top 100 year-on-year growth of 14.0%, growth compared with the previous year, dropped 8.6, 5.5, 1.8, 1.6% respectively. 

 

Wholesale drug companies are growing faster than the industry average, but at a slower pace. 

 

▍ top medicine group accounted for 70% of the currency market 

 

Circulation concentration is improving. From the point of market share, 2016 years ago, 100 pharmaceutical wholesale enterprises main business income accounted for 70.9% of the total scale, the national pharmaceutical market during this period increased by 2.0% over the previous year, the top three pharmaceutical wholesale enterprises accounted for 33.5%, flat with the previous year, the top 10 enterprises accounted for 47.7%, an increase of 0.8% over the previous year, the top 50 enterprises accounted for 65.3%, an increase of 2.2% over the previous year. 

 

The wholesale enterprises, which have a business income of more than 10 billion yuan, accounted for 55.9% of the total pharmaceutical market in China over the same period, up 4.2 percentage points from the previous year. The ranking's last major business revenue grew from 1.15 billion yuan in 2015 to 1.24 billion yuan in 2016. 

 

According to the above data analysis, the market share of the top 100 drug companies is improving. Among them, the top 50 companies are scrambling to catch up to the top companies with a mix of resources. 

 

▍ circulation oligarchs, drug firms both hands 

 

As we all know, the comprehensive implementation of the two-ticket system will strengthen the concentration of the circulation industry. It is predictable that the era of oligarchs will likely emerge in the future. As small drugmakers languish slowly, there will be few companies to choose from. 

 

The implementation of planned in the blue parker "seven times seven of the President of China pharmaceutical enterprise management association (expand) the conference, and 31 Chinese medicine industry development peak BBS", the author on the issue and the CEO of a drug firms do. 

 

"Does your manufacturer not worry about the high concentration of the circulation market, and do you want to distribute the lion's mouth?" 

 

"Don't worry," the boss said, "on the one hand, the formation of circulation oligarchs though is the inevitable trend, but it's not so easy. China resources, national medicine is bad, but all of sasac has pushed companies. Its balance, as long as they don't form the dominance of the country, that will be fine." 

 

"In fact, an area, as long as there are three circulation enterprises competition, for drug firms, is good. If current oligarchs era will come, as an industry, hope a bit faster!" 

 

If this voice has certain representativeness in the production of enterprises, policy leading, drug firms expect, middle circulation enterprises in the following list is more alert. The formation of an oligarchy, the right place and the right place. 

 

Attached: the list of Chinese medical and business associations